15.4 C
New York
Saturday, June 10, 2023

S&P 500 Turns Negative as First U.S. Omicron Case Triggers Uncertainty

S&P 500 Turns Negative as First U.S. Omicron Case Triggers Uncertainty
© Reuters.

By Yasin Ebrahim

Investing.com – The S&P 500 turned negative Wednesday, as investor sentiment was soured by fresh fears about the Omicron coronavirus variant after the U.S. reported its first case of the new strain. 

The S&P 500 fell 0.26%, and had been more than 1% higher intraday. The Dow Jones Industrial Average fell 0.43%, or 148 points, and the Nasdaq slipped 1.1%.

U.S. health officials confirmed Wednesday that the first case of the Omicron variant of Covid-19 was identified in California. The news triggered a bout of uncertainty, with the CBOE Volatility Index, or so-called fear index turning positive, triggering a wave of selling in the broader market and offset positive labor market data.  

Private payrolls grew by 534,000 in November, less than the 570,000 in October, but ahead of expectations for 525,000.

The better-than-expected jobs data comes just days ahead of the monthly nonfarm payrolls due Friday, and strengthened expectations for the Federal Reserve to step up the pace of bond tapering.

In his second day of testimony on Capitol Hill, Fed Chair Jerome Powell continued to reiterate that speeding up the taper of bond purchases would be on the agenda at the December meeting, but added that there was no reason for faster taper to be disruptive to markets.

Utilities, a typically defensive corner of the market, was one of the few sectors in the green.

AES Corporation (NYSE:AES), Alliant Energy (NASDAQ:LNT), WEC Energy (NYSE:WEC) were among the biggest gainers.

In another boost to utilities, which also serve a bond proxy, treasury yields gave up some gains following their intraday surge, with the 10-year U.S. Treasury yields eased further below 1.5%.

Health care stocks were pushed higher by a more than 8% surge in Vertex Pharmaceuticals (NASDAQ:VRTX) after the pharmaceutical company reported a positive update from its mid-stage focal glomerular sclerosis study.

Moderna (NASDAQ:MRNA), meanwhile, slumped more than 11% after losing an appeal against a court ruling on patents – used in the making of its Covid-19 vaccine – held by Arbutus Biopharma (NASDAQ:ABUS). Arbutus surged 36%, but was well off its session highs. 

In energy, Exxon Mobil (NYSE:XOM) was in focus after the oil major forecast a doubling of earnings and cash flow by 2027 amid plans to lower capital expenditure.

In tech, Apple (NASDAQ:AAPL) erased its intraday gains as the broader market reversed. The tech giant was up more than 1% intraday as some on Wall Street highlighted improving signs of improving supply chain pressures that could help the tech maker roll out its latest line of iPhones.

Citing signs of improved wait times for iPhones, UBS forecasts Apple to sell 80 million iPhones in the December quarter, compared with 82 million last year.

Twitter (NYSE:TWTR), meanwhile, fell more than 2% even as Cathie Wood revealed that ARK purchased 1.1 million shares of the social media company on Tuesday, amid optimism about the future of the company under the leadership of new Chief Executive Parag Agrawal.

Source: Investing.com

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected

- Advertisement -

Latest Articles

Popular Articles